Five Below Inc vs Smith & Nephew plc — how do they compare? Five Below Inc trades at $200.21 (market cap $10.67B), while Smith & Nephew plc trades at $31.43 (market cap $12.81B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.54% dividend while Five Below Inc pays none. Which is the better fit depends on your goals.
| FIVE | SNN | |
|---|---|---|
Market Cap | $10.67B | $12.81B |
Sector | Consumer Staples | Health |
52-Week High | $247.71 | $38.70 |
52-Week Low | $131.94 | $28.73 |
Enterprise Value | $11.56B | $15.58B |
Dividend Yield | — | 2.54% |
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $193.11, up 0.82% with a bullish technical signal despite mixed moving averages. The company demonstrates strong growth with revenue reaching $3.88 billion in 2025 and consistent earnings beats, including Q1 2026 EPS of $2.22 beating expectations of $1.77. Valuation metrics show a P/E of 24.34 and P/S of 2.11, while profitability remains solid with 8.67% net margin and 21.13% ROE. Recent news highlights store expansion to 2,000 locations and strategic investments in digital marketing.
FIVE presents a compelling growth story with analyst consensus pointing to 33% upside potential to $252.09 target. The stock benefits from strong institutional support (60% buy ratings) and positive earnings momentum, though investors should monitor competitive pressures in value retail and the sustainability of expansion-driven cash flow patterns. Current technical levels show support at $191 with resistance at $194.
Smith & Nephew (SNN) trades at $29.83, down 4.02% today, with a bearish technical signal. The company reported revenue of $5.81 billion in 2024, with net income of $412 million, showing improved profitability. Recent news highlights product launches in robotics and wound care, supported by a $500 million share buyback. Analyst consensus is mixed, with 27% buy ratings but 68% hold, reflecting cautious optimism amid earnings volatility.
Outlook is balanced: strong free cash flow and innovation in medical technology offer growth potential, but near-term risks include competitive pressures and debt levels. The stock's valuation at a P/E of 21.51 is reasonable if earnings growth sustains, yet technical weakness suggests caution. Investors should weigh solid fundamentals against market sentiment and execution risks.
Trailing returns across standard periods
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →